| Literature DB >> 34007250 |
Yuting Fu1, Hanqing Jin1, Haitao Xiang1, Ning Wang1.
Abstract
As the COVID-19 spreads across the world, many nations impose lockdown measures at the early stage of the pandemic to prevent the spread of the disease. Controversy surrounds the lockdown as it is a choice between economic freedom and public health. The ultimate solution to a pandemic is to vaccinate a massive population to achieve herd immunity. However, the whole vaccination programme is a long and complicated process. The virus and the vaccine will coexist for quite a long time. How to gradually ease the lockdown based on vaccination progress is an important question, as both economic and epidemiological issues are involved. In this paper, we extend the classic SIR model to find optimal decision to balance between economy and public health in the process of vaccination rollout. The model provides an approach of vaccine value estimation. Our results provide scientific suggestion for policymakers to make important decisions on how to gradually relax the strength for the lockdown over the entire vaccination cycle.Entities:
Keywords: COVID-19; Equilibrium; Lockdown; Optimal control; SIR
Year: 2021 PMID: 34007250 PMCID: PMC8119293 DOI: 10.1016/j.frl.2021.102123
Source DB: PubMed Journal: Financ Res Lett ISSN: 1544-6131
Model parameters.
| parameter | value |
|---|---|
| 0.01759 | |
| 0.00233 | |
| 0.38656 | |
| 36.9 | |
| 0.8 | |
Fig. 1Effect of Vaccination on COVID-19 without Lockdown.
Fig. 2Effect of Optimal Lockdown on COVID-19 with Vaccination.
Reduction of Expected Utility of the Susceptible (S), the Infectious (I), and the Recovered (R).
| People Category | S | I | R |
|---|---|---|---|
| Rational Susceptible With Lockdown | 3.8 | 152 | 2.2 |
| Rational Susceptible Without Lockdown | 10.6 | 149.9 | 0 |
| Irrational Susceptible With Lockdown | 3.8 | 152 | 2.2 |
| Irrational Susceptible Without Lockdown | 28.1 | 149.9 | 0 |
Reduction of Accumulated Utility of the Susceptible (S), the Infectious (I), and the Recovered (R).
| Initial Infectious Population | 0.002 | 0.005 | 0.01 |
|---|---|---|---|
| Rational Susceptible | 3.9 | 5.9 | 7.1 |
| Irrational Susceptible | 8.7 | 17.2 | 25.4 |
Vaccine company and price.
| Company | Price( |
|---|---|
| AstraZeneca | 2.2-2.9 |
| Johnson & Johnson | 7.3 |
| Novavax | 11.6 |
| Pfizer | 15 |
| Moderna | 25 |